INTRODUCTION

Pancreatic cancer has the poorest prognosis of any cancer. Pancreatic cancer is the third leading cause of cancer-related mortality in the United States, with a 5-year overall survival of 9%; an estimated 47,050 Americans will die of the disease in 2020.1 Globally, in 2018, 458,918 pancreatic cancer diagnoses were made, comprising 2.5% of worldwide cancer cases, and 432,242 deaths contributed to 4.5% of worldwide cancer-related deaths.2 Approximately 95% of pancreatic cancers originate from exocrine cells, most commonly pancreatic ductal adenocarcinomas (PDAC).3 Endocrine pancreatic cancers generally have a more favorable prognosis.4 Ductal adenocarcinoma is the most common malignancy of the pancreas. Accordingly, this tumor presents a substantial health problem worldwide.5,6

Through exome sequencing of PDAC surgical specimens, in a very interesting study, Biankin et al demonstrated that the axon guidance gene family was the most frequently altered gene family, indicating involvement of the nervous system in PDAC carcinogenesis. Moreover, perineural invasion has been widely identified as one poor prognostic factor. The combination of innovative technologies and extensive clinician experience with the nervous system come together here to create a new treatment option. However, evidence has emerged that suggests that the relationship between cancer and nerves in PDAC, the underlying mechanism, is not fully understood. In an attempt to tackle this lethal cancer, this review summarizes the anatomy and physiology of the pancreas and discusses the role of the nervous system in the pathophysiology of PDAC.

KEYWORDS
axon guidance, nerve growth factors, neurotrophic tyrosine kinase receptor, pancreatic neoplasms, tumor microenvironment

1 | INTRODUCTION

Pancreatic cancer has the poorest prognosis of any cancer. Pancreatic cancer is the third leading cause of cancer-related mortality in the United States, with a 5-year overall survival of 9%; an estimated 47,050 Americans will die of the disease in 2020.1 Globally, in 2018, 458,918 pancreatic cancer diagnoses were made, comprising 2.5% of worldwide cancer cases, and 432,242 deaths contributed to 4.5% of worldwide cancer-related deaths.2 Approximately 95% of pancreatic cancers originate from exocrine cells, most commonly pancreatic ductal adenocarcinomas (PDAC).3 Endocrine pancreatic cancers generally have a more favorable prognosis.4 Ductal adenocarcinoma is the most common malignancy of the pancreas. Accordingly, this tumor presents a substantial health problem worldwide.5,6

Through exome sequencing of PDAC surgical specimens, in a very interesting study, Biankin et al demonstrated that the axon guidance gene family was the most frequently altered gene family.7 Their findings suggest the potential involvement of the nervous system in PDAC carcinogenesis. Moreover, perineural invasion has been widely identified as one poor prognostic factor. The combination of innovative technologies and extensive clinician experience with the nervous system come together here to create a new treatment option. However, evidence has emerged that suggests that the relationship between cancer and nerves in PDAC, the underlying mechanism, is not fully understood. In an attempt to tackle this lethal cancer, this review summarizes the anatomy and physiology of the pancreas and discusses the role of the nervous system in the pathophysiology of PDAC.
gastrointestinal malignancies. Furthermore, the PNI severity is more severe compared to other gastrointestinal malignancies. However, it remains unclear why PDAC is associated with a higher incidence of PNI.

The inhibition of PNI would have the potential for improving prognosis in patients with PDAC. However, neither the underlying mechanism of PNI nor the crosstalk between cancer cells and nerves within PNI has been fully understood. Furthermore, the role of nerves in PDAC initiation and progression has remained unclear. It is assumed that the elucidation of these biological phenomena will provide new treatment strategies targeting nerve-cancer signaling that prevent PNI and improve survival in PDAC patients.

In this review, we describe a brief overview of the anatomy and physiology of the pancreas. Then, we discuss novel possibilities for the role of nerves in PDAC, mainly focusing on nerve-cancer interactions.

2 | CLINICAL ANATOMY OF THE PERIPANCREATIC NERVE PLEXUS

The pancreas has an abundant nerve supply. Many nerve branches supply the pancreas and form several nerve plexuses. In the General Rules for the Study of Pancreatic Cancer edited by the Japan Pancreatic Society, these extrapancreatic nerve branches are divided into seven plexuses as follows: the pancreatic head nerve plexus I (PLphl), the pancreatic head nerve plexus II (PLphll), the superior mesenteric nerve plexus (PLsms), the common hepatic nerve plexus (PLchn), the hepatoduodenal ligament nerve plexus (PLhdnl), the splenic artery nerve plexus (PLsplits), and the celiac plexus (PLc).

Figure 1 shows the schema of the nervous system around the pancreas. The nerves serving the pancreas head mainly derive from the celiac plexus. They are divided into the anterior hepatic plexus running along the common hepatic artery, and the posterior hepatic plexus running through the depths and behind the portal venous system. Innervation of the pancreas head is largely thanks to the posterior hepatic plexus originating from the right celiac ganglion, which is equivalent to the “pancreatic head nerve plexus I” reported by Yoshioka and Wakabayashi.

The innervation of the uncinate process of the pancreas originates from the superior mesenteric plexus. The nerve is divided into two pathways: the direct pathway and the accompanying pathway. Pancreatic head nerve plexus II from the superior mesenteric arterial plexus directly entering the uncinate process is considered the direct pathway. The accompanying pathway is the nerve along the inferior pancreaticoduodenal artery.

The innervation of the body and tail of the pancreas is divided into two routes. One route, derived from the splenic plexus, branches into the body and tail directly or passes along the great pancreatic artery and the dorsal pancreatic artery. The other originates from the celiac plexus and directly enters the pancreatic parenchyma at the neck of the pancreas. One branch of the celiac plexus runs to the parenchyma along the inferior pancreatic artery and is distributed mainly into the lower body and tail of the pancreas. This branch achieves communication in the periphery with the branch of the splenic plexus. The other celiac plexus branch is distributed around the pancreatic duct without the accompanying artery.

Those peripancreatic nerve plexuses involved in the sensory nerve and autonomic nervous system include the sympathetic, parasympathetic, and enteric divisions.

3 | THE INNERVATION OF THE PANCREAS

The pancreas consists of two functional components. The exocrine pancreas, occupying a major portion of the pancreas, consists of acinar cells and ductal cells. This part releases digestive enzymes and bicarbonate into the duodenum. The endocrine pancreas is organized into the islets of Langerhans. The endocrine pancreas secretes hormones, including insulin, glucagon, ghrelin, pancreatic polypeptide, and somatostatin. Both components of the pancreas are innervated by the autonomic nervous system, and regulated by the separate pathways for normal activity.

3.1 | Parasympathetic neurons

Preganglionic parasympathetic neurons originate from the dorsal motor nucleus of the vagus. This activates parasympathetic postganglionic neurons in the pancreatic ganglia, primarily via activation of nicotinic acetylcholine receptors. Various neurotransmitters and neuromodulators can regulate these transmissions between pre- and postganglionic neurons. The distribution of parasympathetic neurons is wider than that of sympathetic neurons, with some overlapping regions. The postganglionic neurons release several neurotransmitters, which are excitatory or inhibitory depending upon the receptor. One typical neurotransmitter is acetylcholine (Ach), which binds to muscarinic receptors and produces a tonic input. Nitric oxide
with blood vessels. Some studies have suggested that sensory nerve terminations of the solitary tract is the strongest candidate. Activation of the parasympathetic nerve mainly leads to excitation, which results in increases of both exocrine and endocrine secretion.

3.2 Sympathetic neurons

Preganglionic sympathetic neurons originate from the lower thoracic and upper lumbar segments of the spinal cord. They exit the spinal cord through the ventral roots and reach either the paravertebral ganglia of the sympathetic chain or the celiac and mesenteric ganglia. The postganglionic sympathetic nerve terminates at the intrapancreatic ganglia, islets, and pancreatic blood vessels. Although it is modest compared to islets and blood vessels, some sympathetic nerves project to acinar cells and ducts. They release various neurotransmitters, including norepinephrine (NE), galanin, and neuropeptide Y. Sympathetic nerves primarily decrease plasma insulin levels. Conversely, stimulation of the sympathetic nerves increases glucagon secretion. These findings suggest that the overall effect of the sympathetic nerves on endocrine function is to maintain glycemic levels during stressful conditions. The sympathetic nerve primarily inhibits pancreatic exocrine secretion; however, what the definitive effect is remains controversial.

3.3 Enteric neurons

The enteric nervous system is the third division of the autonomic nervous system. The enteric nerve from within the gastric antrum wall and the proximal duodenum wall reaches the intrapancreatic ganglia. The enteric fiber can release multiple neurotransmitters and neuromodulators, including Ach, serotonin, PACAP, and NO. Some studies have indicated a relationship between the enteric nerve and pancreatic function. However, the role of the nerve in controlling the endocrine and exocrine functions in humans is not yet fully understood.

3.4 Sensory neurons

The sensory nerves of the pancreas reach the central nervous system via both the vagal and spinal routes. Although the central targets of vagal afferents have not been fully established, the nucleus of the solitary tract is the strongest candidate. Sympathetic and parasympathetic afferent nerves are capsaicin-sensitive, and contain substance P and calcitonin gene-related peptide, or both. Mechanosensitive fibers are primarily associated with blood vessels. Some studies have suggested that sensory nerves may inhibit insulin secretion and exocrine secretion. However, the role of sensory nerves on pancreatic functions has not been fully proven.

4 THREE-DIMENSIONAL MICROSCOPIC FINDINGS OF THE PANCREATIC INNERRVATION

Thanks to two innovative technologies, tissue clearing and advanced microscopy, we have been able to distinctly visualize three-dimensional (3D) anatomy and pathology. These technological advances definitely contribute to further organizing knowledge of the pancreatic nerves. Tang et al. visualized the neuro-insular network via 3D histology. They demonstrated that both the sympathetic and parasympathetic nerves enter the islet and reside in the islet cell’s immediate microenvironment. They also found the intrapancreatic ganglia (perilobular and intraparenchymal ganglia) and the islet-ganglionic association around the islets. Intrapancreatic ganglia include pancreatic neurons, glial cells, and extrinsic and intrinsic nerve fibers. These results provide novel insights into human pancreatic disease.

On the other hand, the relationship between the nerves and exocrine components has not been a center of focus. With 3D histology, our colleagues have visualized the nerve fiber networks around the pancreatic acinar cells and duct cells in the human pancreas (Figure 2).

5 NERVE-CANCER CROSSTALK WITHIN PNI IN PDAC

A century ago, PNI was identified as one of the routes for metastatic spread. Recently, our ability to understand the molecular mechanisms behind PNI has become clearer. Several lines of evidence from current studies have caused a paradigm shift in our recognition of PNI. In short, they have indicated that PNI is a metastatic route as well as a critical command center during the progression of PDAC. We next discuss the role of nerves in PDAC. We attempt to clarify how nerves contribute to the pathogenesis of PDAC.

5.1 Nerve-mediated development and organ patterning in the pancreas

During the initial phase of cancer progression, tumors activate nerve-dependent pathways similar to those in normal development. Thus, we first provide a brief overview of nerve-mediated development and organ patterning. To understand nerve-mediated development and organ patterning in the normal pancreas, research findings using the submandibular gland, which also has acini and ducts, are helpful. During gland development, a variety of cells, including the epithelial, mesenchymal, and stromal cells, secrete...
various neurotrophins to elicit the recruitment of the peripheral nerves. This phase is called the nerve recruitment phase.\(^7^9\)

To date, several neurotrophins and their cognate receptors have been identified. There are four neurotrophins recognized in humans: the prototypical nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3), and neurotrophin 4/5 (NT-4/5).\(^8^0\) In addition, some polypeptide factors, including ciliary neurotrophic factor (CNTF),\(^8^1\) and glial cell line-derived neurotrophic factor (GDNF),\(^8^2\) possess neurotrophic activity.\(^8^0\) The biological effects of each of the four neurotrophins are mediated through activation of one or more of the three members of the tropomyosin-related kinase (Trk) family of receptor tyrosine kinases (TrkA, TrkB, and TrkC). In addition, all neurotrophins activate the p75 neurotrophin receptor (p75 NTR), a member of the tumor necrosis factor receptor superfamily.\(^8^0\) The cognate receptor of GDNF is GDNF family receptor-\(\alpha\)\(^2\) (GFR\(\alpha\)\(^2\)).\(^8^3\) Neurotrophin binding to the receptor on nerves leads to retrograde signals that travel from the distal axon to the cell body and dendrites. These signals promote gene expression and axogenesis.\(^8^4,8^5\)

After the nerve recruitment phase, parasympathetic nerves initiate ductal epithelial tubulogenesis through VIP signaling.\(^8^6\) Additionally, parasympathetic nerves also regulate glandular or acinar epithelium growth and patterning through ACh signaling by activating SRY-box 2 (SOX2).\(^8^7\) On the other hand, sympathetic nerves are necessary for patterning the vasculature in gland development.\(^8^8,8^9\) In the developing pancreas, adrenergic innervation is associated with a rapid phase of glandular growth and maturation. Conversely, the deletion of neurotrophin or their receptors leads to the disruption of the glandular architecture.\(^9^0,9^1\) In summary, the nerve and nerve-mediated pathways are essential to the development and organ patterning of the pancreas.

### 5.2 | Vicious cycle between the nervous system and cancer cells

In cancer, to continue to grow and be maintained, tumor cells and the surrounding reactive stroma release neurotrophins to recruit nerves.\(^7^9,9^2\) These tumor-derived neurotrophins result in axogenesis of the autonomic nerve and the sensory nerve.\(^9^3\) After the nerve recruitment phase in cancer, each nerve contributes to the growth phase of the cancer. Sympathetic nerves generate neovascularization, similar to what happens in tissue development.\(^9^4\) Through mitosis, parasympathetic nerves activate tumor cells, which starts growth expansion.\(^9^5\) Parasympathetic nerves also give tumor cells migratory cues for metastasis.\(^9^6\) Furthermore, cancer cells migrate along the nerve and invade into nerves in response to various mediators released by the peripheral nerves and nerve resident macrophages.\(^8^9,9^7-10^3\)

In short, cancer cells themselves create a favorable environment for cancer by modulating neural systems. Unfortunately, these nerve-cancer interactions can cause a fatal vicious cycle in PDAC. Based on characteristic findings, including the abundant nerve supply to the pancreas and the higher frequency and degree of PNI, this lethal downstream spiral in PDAC may be greater than in other cancers, which may be one reason that PDAC has one of the poorest prognoses.

### 5.3 | Increased nerve density in PDAC specimens

During cancer progression from preneoplastic lesions to cancer, increased nerve density is a significant feature in neoplastic tissue.\(^9^4,10^4\) Furthermore, increased nerve density has been found to correlate consistently with more aggressive disease,\(^10^5,10^6\) including pancreatic cancer.\(^10^7\) In the pancreatic intraepithelial neoplasia (PanIN), increased nerve density has been demonstrated.\(^10^8,10^9\) Moreover, as expected from the result in PanIN, a drastically increased number and size of intrapancreatic nerves were observed in PDAC.\(^9^9,11^0\) This observation is termed pancreatic cancer-associated neural remodeling (PANR).\(^10^2,11^1,11^2\) Several lines of evidence revealed that an increase in nerve density is paralleled by an increase in neurotrophin production.\(^9^4,10^4,10^8,11^3\) Stopczynski et al reported that neurotrophins as well as their cognate receptors increased early in the development of PDAC.\(^10^9\) In human PDAC specimens, interestingly, neurotrophin expression was primally within the stromal compartment, not within the epithelial compartment.\(^11^4,11^5\) Our 3D image of cleared human PDAC, visualized by Dr Yoshizawa, clearly demonstrated the increased nerve density compared to the normal pancreas, which accurately confirms previous reports (Figure 2).
To date, there have been several lines of evidence for the neural modulation effect in PDAC (Table 1). Furthermore, neural modulation, by the denervation of the vagus nerve or sensory nerves, would potentially inhibit progression from the PanIN stage to PDAC.\textsuperscript{108,116-119} Targeting these signaling pathways may prove useful in the treatment of PDAC.

### TABLE 1 Evidence for neural regulation in PDAC

| Target                  | Findings                                                                 | Ref. |
|-------------------------|---------------------------------------------------------------------------|------|
| Parasympathetic nerves  | Nicotine induces tumor metastasis via the α7nAChR/JAK2/STAT3 downstream signaling cascade | 132  |
|                        | Subdiaphragmatic vagotomy accelerates tumorigenesis                       | 118  |
|                        | Muscarinic agonist suppresses tumorigenesis via MAPK and PI3K/ Akt signaling |      |
| Sympathetic nerves      | NE inhibits migratory activity via imbalanced activation of PKC/PLC signaling | 133  |
|                        | Catecholamines promote the secretion of NT, which in turn promotes increased NE and tumor growth | 114  |
|                        | NE promotes PNI via β-AR/PKA/STAT3 signaling                                | 134  |
| Sensory nerves          | Ablation of sensory neurons slows initiation and progression               | 116  |
|                        | SP induces PNI via NK-1R signaling                                        | 135  |
|                        | Increased sensory innervation and NT linked with disease progression from premalignant stages to cancer | 109  |
|                        | Sensory nerves promote PanIN tumorigenesis via NK-1R signaling             | 108  |
| NT                      | GDNF/GFRα1-RET signaling in a paracrine manner promotes PNI via MAPK      | 99   |
|                        | GDNF/GFRα1-RET signaling derived from endoneurial macrophages promotes PNI via MAPK/PI3K | 126  |
|                        | nerve-released GFRα1 enhances PNI through GDNF/RET signaling              | 97   |
|                        | NRTN/GFRα2 signaling derived from tumor cells promotes invasiveness       | 137  |
|                        | Artemin/GFRα3-RET signaling promotes cancer invasion                      | 138  |
|                        | Schwann cells are chemoattracted to cancer cells via NGF/p75<sub>NTR</sub> interaction | 139  |
|                        | NGF/TrkA expression is associated with PNI                                 | 140  |
| Other factors           | SDC-2 expression is associated with PNI                                    | 141  |
|                        | PSCs affected by paracrine SHH signaling promote PNI                       | 142  |
|                        | TGFβ/SMAD signaling derived from Schwann cells enhance aggressiveness and PNI | 102  |
|                        | Axon guidance factor SLIT2/ROBO signaling inhibits PNI and metastasis     | 121  |
|                        | Axon guidance factor SEMA3/PLXNA1 promotes tumor dissemination             | 143  |
|                        | Axon guidance factor SEMA3D/PLXND1 induces tumor invasion                 | 11,120|

Abbreviations: Ach, acetylcholine; AKT, serine/threonine kinase or protein kinase B; GDNF, glial cell-derived neurotrophic factor; GFRα, GDNF family receptor-α; JAK2, janus kinase 2; MAPK, mitogen-activated protein kinase; nAChR, nicotinic acetylcholine receptor; NE, norepinephrine; NGF, nerve growth factor; NK-1R, neurokinin-1 receptor; NRTN, neurtitin; NT, neurotrophin; PanIN, pancreatic intraepithelial neoplasms; PI3K, phosphoinositide 3-kinase; PKA, protein kinase A; PKC, protein kinase C; PLC, phospholipase C; PLXN, plexin; PI3K, perineural invasion; PSCs, pancreatic stellate cells; RET, Ret proto-oncogene; ROBO, roundabout; SDC, syndecan; SHH, Sonic Hedgehog; SLIT2, slit guidance ligand 2; SP, substance P; STAT3, signal transducer and activator of transcription 3; TGFβ, transforming growth factor beta; Trk, tropomyosin-related kinase.

### 5.4 Evidence for neural modulation in PDAC

To date, there have been several lines of evidence for the neural modulation effect in PDAC (Table 1). Furthermore, neural modulation, by the denervation of the vagus nerve or sensory nerves, would potentially inhibit progression from the PanIN stage to PDAC.\textsuperscript{108,116-119} Targeting these signaling pathways may prove useful in the treatment of PDAC.

Regarding axon guidance molecules, there have been some findings of semaphorin and its receptors, plexin. Jurcak et al demonstrated that a PNI mechanism is associated with the semaphorin and plexin gene family in PDAC using mice.\textsuperscript{11} They further reported increased levels of semaphorin and plexin in human PDAC specimens associated with PNI. Moreover, human PDAC semaphorin expression is associated with poor survival and metastasis.\textsuperscript{120} These results suggest that strategies to disrupt the axon guidance pathway...
FIGURE 3  Targeting neurotrophins is one candidate for a new treatment strategy for PDAC. We retrieved associated molecules from QIAGEN Ingenuity Pathway Analysis. This network was generated, mainly focusing on TRK, through the use of QIAGEN Ingenuity Pathway Analysis. Direct interactions are shown in this network (excluding indirect interactions). The molecules with the green outline are components of the canonical pathway of axon guidance signaling. The nodes filled in with yellow are neurotrophins, their receptors. Emerging evidence has shown that TRK inhibitors (blue) link together with the yellow nodes (blue arrow lines). Furthermore, we have delineated the molecules of axon guidance signaling, which previously have demonstrated a direct relationship to not only cancer growth but also neurotrophins and their receptors. This network reveals that neurotrophins and their receptors are linked to PDAC progression via various molecules and signaling pathways. The established network reveals that several tropomyosin receptor kinase inhibitors would have anti-cancer effects by suppressing the neurotrophin-related pathways in PDAC.
mediated by semaphorin might be developed to slow the progression of PDAC. However, SLIT2/ROBO signaling, one of the axon guidance factors, inhibits PNI and metastasis in PDAC.121 When considering this conflicting information together, it becomes evident that the role of the axon guidance molecules in PDAC is complicated. More precise characterization is needed to explore new pharmacological approaches targeting molecules.

Tropomyosin receptor kinase (TRK) has been focused on as a new treatment target, because there are actionable inhibitors such as larotrectinib and entrectinib.122-125 To visualize the role of TRK and the entire relationship with PDAC, we generated a TRK-related network through the use of QIAGEN Ingenuity Pathway Analysis126 (Figure 3). The evidence that emerged has demonstrated the efficacy of TRK inhibitor in patients with the neurotrophic tyrosine receptor kinase (NTRK) gene fusion-positive.123,127,128 Although rare, NTRK gene fusions are identified as oncogenic drivers in <1% of PDAC cases,122,129-131 thus providing a potential treatment target.

6 | FUTURE DIRECTIONS

Based on several lines of evidence elucidated here, what we next want to find out is how neural regulation progresses after curative surgery. Because we have generally performed peripancreatic nerve plexus dissection, a better understanding of how nerve dissection affects the remnant pancreas and tumor microenvironment is highly significant to preventing local recurrence after curative surgery.

Unfortunately, there has not been a clinical or experimental study to assess the effect of residual nerves on tumor recurrence after curative surgery. Based on the previous reports, we can speculate that residual nerves induced/activated by cancer cells could continue to stimulate oncogenesis, cancer growth, and cancer progression even after R0 resection. Furthermore, an immune system modified by tumor-induced nerves could also contribute to increase cancer growth.93 We really want to know whether the modification applied to the nerve by the switch from cancer cells is reversible or irreversible. If this modification remains irreversible even after R0 resection and promotes postoperative recurrence, we need to inhibit the nerve-induced positive regulation in cancer growth. For that purpose, potential therapeutic options would be based on stopping aberrant tumor neurogenesis and disrupting communication among cancer cells, leukocytes, and neurons.

Innovative pharmacological strategies targeting the nervous system and neurotrophins may improve the prognosis of PDAC patients by inhibiting carcinogenesis, invasiveness, metastasis, and local recurrence. Therefore, a further, deeper understanding of the nerve-cancer interaction is needed for clinicians treating PDAC and their patients.

ACKNOWLEDGEMENTS

We sincerely thank Shari Joy Berman for professionally editing the English draft of this manuscript.

DISCLOSURE

Funding: There was no funding for this study.

Conflict of interest: The authors have no conflicts of interest to declare.

ORCID

Taiichi Wakiya https://orcid.org/0000-0003-3681-7736
Keinosuke Ishido https://orcid.org/0000-0002-0342-1199
Tadashi Yoshizawa https://orcid.org/0000-0001-8136-3281
Taishu Kanda https://orcid.org/0000-0003-2839-3347
Kenichi Hakamada https://orcid.org/0000-0001-6513-1202

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
3. Grossberg AJ, Chu LC, Deig CR, Fishman EK, Hwang WL, Maitra A, et al. Multidisciplinary standards of care and recent progression in pancreatic ductal adenocarcinoma. CA Cancer J Clin. 2020;70(5):375–403.
4. Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2018;68:471–87.
5. Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016;2(1):16022.
6. Ishido K, Hakamada K, Kimura N, Miura T, Wakiya T. Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg. 2021:5:7–23.
7. Biankin AV, Waddell N, Kassahn KS, Gingras M-C, Muthuswamy LB, Johns AL, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491:399–405.
8. Amit M, Na'ara S, Gil Z. Mechanisms of cancer dissemination along nerves. Nat Rev Cancer. 2016;16:399–408.
9. Demir IE, Ceyhan GO, Liebl F, D’Haese JG, Maak M, Friess H. Neural invasion in pancreatic cancer: the past, present and future. Cancers. 2010;2:1513–27.
10. Liebig C, Ayala G, Wilks JA, Berger DH, Albo D. Perineural invasion in cancer: a review of the literature. Cancer. 2009;115:3379–91.
11. Jurcak NR, Rucki AA, Muth S, Thompson E, Sharma R, Ding D, et al. Axon guidance molecules promote perineural invasion and metastasis of orthotopic pancreatic tumors in mice. Gastroenterology. 2019;157(3):838–850.e6.
12. Dwiwedi S, Krishnan A. Neural invasion: a scenic trail for the nervous tumor and hidden therapeutic opportunity. Am J Cancer Res. 2020;10:2258–70.
13. Alrawashdeh W, Jones R, Dumartin L, Radon TP, Cutilias PR, Feakins RM, et al. Perineural invasion in pancreatic cancer: proteomic analysis and in vitro modelling. Mol Oncol. 2019;13:1075–91.
14. Makino I, Kitagawa H, Ohta T, Nakagawara H, Tajima H, Ohnishi I, et al. Nerve plexus invasion in pancreatic cancer: spread patterns on histopathologic and embryological analyses. Pancreas. 2008;37:358–65.
15. Nakao A, Harada A, Nonami T, Kaneko T, Takagi H. Clinical significance of carcinoma invasion of the extrapancreatic nerve plexus in pancreatic cancer. Pancreas. 1996;12:357–61.
16. Schorn S, Demir IE, Haller B, Scheufele F, Reyes CM, Tieftrunk E, et al. The influence of neural invasion on survival and tumor
recurrence in pancreatic ductal adenocarcinoma - A systematic review and meta-analysis. Surg Oncol. 2017;26:105–15.

17. Liebl F, Demir IE, Mayer K, Schuster T, D’Haese JG, Becker K, et al. The impact of neural invasion severity in gastrointestinal malignancies: a clinicopathological study. Ann Surg. 2014;260(5):900–7; discussion 7–8.

18. Cartwright T, Richards DA, Boehm KA. Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network. Cancer Control. 2008;15:308–13.

19. Lowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006;20:197–209.

20. Yi SQ, Miwa K, Ohta T, Kayahara M, Kitagawa H, Tanaka A, et al. Innervation of the pancreas from the perspective of perineural invasion of pancreatic cancer. Pancreas. 2003;27:225–9.

21. Dolenšek J, Rupnik MS, Stožer A. Structural similarities and differences between the human and the mouse pancreas. Islets. 2015;7:e1024405.

22. Wang X, Zhang H, Wang T, Lau WY, Wang X, Sun J, et al. The concept and controversy of retroperitoneal nerve dissection in pancreatic head carcinoma (Review). Int J Oncol. 2015;47:2017–27.

23. Classification of Pancreatic Carcinoma, Fourth English ed. Japan Pancreas Society: Kanehara & Co., Ltd., 2017.

24. Ren K, Yi S-Q, Dai Y, Kurosawa K, Miwa Y, Sato I. Clinical anatomy of the anterior and posterior hepatic plexuses, including relations with the pancreatic plexus: a cadaver study. Clin Anat. 2020;33:630–6.

25. Yi SQ, Nagakawa Y, Ren K, Dai Y-D, Zhang M, Chen J-F, et al. The mesopancreatic and pancreatic head plexus: morphological, developmental, and clinical perspectives. Surg Radiol Anat. 2020;42:1501–8.

26. Yoshioka H, Wakabayashi T. Therapeutic neurotomy on head of pancreas for relief of pain due to chronic pancreatitis; a new technique and its results. AMA Arch Surg. 1958;76:546–54.

27. Chien HJ, Chiang TC, Peng SJ, Chung M-H, Chou Y-H, Lee C-Y, et al. Human pancreatic afferent and efferent nerves: mapping and 3-D illustration of exocrine, endocrine, and adipsive innervation. Am J Physiol Gastrointest Liver Physiol. 2019;317:G694–G706.

28. Ahrén B. Autonomic regulation of islet hormone secretion--implications for health and disease. Diabetologia. 2000;43:393–410.

29. Kiba T. Relationships between the autonomic nervous system and the pancreas including regulation of regeneration and apoptosis: recent developments. Pancreas. 2004;29:e51–e58.

30. Travagl RA, Anselmi L. Vagal neurocircuitry and its influence on gastric motility. Nat Rev Gastroenterol Hepatol. 2016;13:389–401.

31. Demir IE, Friess H, Ceyhan GO. Neural plasticity in pancreatitis and pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2015;12:649–59.

32. Love JA, Yi E, Smith TG. Autonomic pathways regulating pancreatic exocrine secretion. Auton Neurosci. 2007;133:19–34.

33. Travagl TB, Alberto R. Neural control of the pancreas. Pancreapaedia: the exocrine pancreas knowledge base. 2020.

34. Browning KN, Travagl RA. Plasticity of vagal brainstem circuits in the control of gastrointestinal function. Auton Neurosci. 2011;161:6–13.

35. Gilon P, Henquin JC. Mechanisms and physiological significance of the cholinergic control of pancreatic beta-cell function. Endocrin Rev. 2001;22:565–604.

36. Di Caïrano ES, Moretti S, Marciani P, Sacchi VF, Castagna M, Davalli A, et al. Neurotransmitters and neuropeptides: new players in the control of islet of langerhans' cell mass and function. J Cell Physiol. 2016;231:756–67.

37. Wan S, Browning KN, Travagl RA. Glucagon-like peptide-1 modulates synaptic transmission to identified pancreas-projecting vagal motoneurons. Peptides. 2007;28:2184–91.

38. Babic T, Bhagat R, Wan S, Browning KN, Snyder M, Fortna SR, et al. Role of the vagus in the reduced pancreatic exocrine function in copper-deficient rats. Am J Physiol Gastrointest Liver Physiol. 2013;304:G437–G448.

39. Babic T, Browning KN, Kawaguchi Y, Tang X, Travagl RA. Pancreatic insulin and exocrine secretion are under the modulatory control of distinct subpopulations of vagal motoneurons in the rat. J Physiol. 2012;590:3611–22.

40. Berthoud HR, Fox EA, Powley TL. Localization of vagal peptidomics that stimulate insulin and glucagon secretion. Am J Physiol. 1990;258:R160–R168.

41. Browning KN, Travagl RA. Pancreatic polypeptide, microinjected into the dorsal vagal complex, potentiates glucose-stimulated insulin secretion in the rat. Regul Pept. 1995;60:185–92.

42. Li Y, Hao Y, Owuyang C. High-affinity CCK-A receptors on the vagus nerve mediate CCK-stimulated pancreatic secretion in rats. Am J Physiol. 1997;273:G679–G685.

43. Okumura T, Pappas TN, Taylor IL. Pancreatic polypeptide microinjection into the dorsal motor nucleus inhibits pancreatic secretion in rats. Gastroenterology. 1995;108:1517–25.

44. Mussa BM, Verberne AJ. The dorsal motor nucleus of the vagus and regulation of pancreatic secretion. Exp Physiol. 2013:98:25–37.

45. Nishi S, Seino Y, Ishida H, Seno M, Taminato T, Sakurai H, et al. Vagal regulation of insulin, glucagon, and somatostatin secretion in vitro in the rat. J Clin Invest. 1987;79:1191–6.

46. Ionescu E, Rohner-Jeanrenaud F, Berthoud HR, Jeanrenaud B. Increases in plasma insulin levels in response to electrical stimulation of the dorsal motor nucleus of the vagus nerve. Endocrinology. 1983;112:904–10.

47. Furuzawa Y, Ohmori Y, Watanabe T. Anatomical localization of sympathetic postganglionic and sensory neurons innervating the pancreas of the cat. J Vet Med Sci. 1996;58:243–8.

48. Llewellyn-Smith AJ. Anatomy of synaptic circuits controlling the activity of sympathetic preganglionic neurons. J Chem Neuroanat. 2009;38:231–9.

49. Loukas M, Klaassen Z, Merbs W, Tubbs RS, Gielecki J, Zurada A. A review of the thoracic splanchnic nerves and celiac ganglia. Clin Anat (New York, NY). 2010;22:512–22.

50. Havel PJ, Taborsky GJ Jr. The contribution of the autonomic nervous system to changes of glucagon and insulin secretion during hypoglycemic stress. Endocr Rev. 1989;10:332–50.

51. Yi E, Smith TG, Baker RC, Love JA. Catecholamines and 5-hydroxytryptamine in tissues of the rabbit exocrine pancreas. Pancreas. 2004;29:218–24.

52. Ahrén B. Regulation of insulin secretion by nerves and neuropeptides. Ann Acad Med, Singapore. 1999;28:99–104.

53. Yi E, Smith TG, Love JA. Noradrenergic innervation of rabbit pancreatic ganglia. Auton Neurosci. 2005;117:9-13.

54. Ahrén B, Veith RC, Paquette TL, Taborsky GJ Jr. Sympathetic nerve stimulation versus pancreatic norepinephrine infusion in the dog: 2). Effects on basal release of somatostatin and pancreatic polypeptide. Endocrinology. 1987;121:322–9.

55. Andersson PO, Holst J, Järhult J. Effects of adrenergic blockade on the release of insulin, glucagon and somatostatin from the pancreas in response to splanchic nerve stimulation in cats. Acta Physiol Scand. 1982;116:403–9.

56. Dunning BE, Ahrén B, Veith RC, Taborsky GJ Jr. Nonadrenergic sympathetic neural influences on basal pancreatic hormone secretion. Am J Physiol. 1988;255:E785–E792.

57. Holst J, Schwartz TW, Knuhtsen S, Jensen SL, Nielsen OV. Autonomic nervous control of the endocrine secretion from the isolated, perfused pig pancreas. J Auton Nerv Syst. 1986;17:71–84.

58. Kurose T, Seino Y, Nishi S, Tsuji K, Taminato T, Tsuda K, et al. Mechanism of sympathetic neural regulation of
insulin, somatostatin, and glucagon secretion. Am J Physiol. 1990;258:E220–E227.

59. Ahrén B, Veith RC, Taborsky GJ Jr. Sympathetic nerve stimulation versus pancreatic norepinephrine infusion in the dog: 1. Effects on basal release of insulin and glucagon. Endocrinology. 1987;121:323–31.

60. Ahrén B, Veith RC, Taborsky GJ Jr. The effects of epinephrine on islet hormone secretion in the dog. Int J Pancreatol. 1988;3:375–88.

61. Ross MH, Pawlina W, eds. Histology: A Text and Atlas: with Correlated Cell and Molecular Biology. Alphen aan den Rijn, Netherlands; Philadelphia, PA: Wolters Kluwer Health; 2016.

62. Furness JB. The enteric nervous system and neurogastroenterology. Nat Rev Gastroenterol Hepatol. 2012;9:28–94.

63. Chandrasekharan B, Srinivasan S. Diabetes and the enteric nervous system. Neurogastroenterol Motil. 2007;19:951–60.

64. Li W, Yu G, Liu Y, Sha L. Intrapancreatic ganglia and neural regulation of pancreatic endocrine secretion. Front Neurosci. 2019;13:21.

65. Kirchgessner AL, Liu MT. Presynaptic inhibition by serotonin of nerve-mediated secretion of pancreatic amylase. Am J Physiol. 1995;268:G339–G345.

66. Kirchgessner AL, Gershon MD. Innervation of the pancreas by vagal sensory neurones in the rat by retrograde demonstration of pancreatic afferents in the mouse. J Comp Neurol. 2008;509:42–52.

67. Rodriguez-Diaz R, Caicedo A. Neural control of the endocrine pancreas. Best Pract Res Clin Endocrinol Metab. 2001;262:91–100.

68. Kirchgessner AL, Gershon MD. Innervation of the pancreas by nerves in the gut. J Neurosci. 1990;10:1626–42.

69. Rodríguez-Díaz R, Caicedo A. Neural control of the endocrine pancreas. Best Pract Res Clin Endocrinol Metab. 2014;28:745–56.

70. Fasanella KE, Christianson JA, Chanthaphavong RS, Davis BM. Distribution and neurochemical identification of pancreatic afferents in the mouse. J Comp Neurol. 2008;509:42–52.

71. Shanker KA, Williams RG. Extrinsic innervation of the rat pancreas: demonstration of vagal sensory neurones in the rat by retrograde tracing. Neurosci Lett. 1983;42:131–5.

72. Shanker KA, Williams RG, Dockay GJ. Sensory substance P innervation of the stomach and pancreas. Demonstration of capsaicin-sensitive sensory neurones in the rat by combined immunohistochemistry and retrograde tracing. Gastroenterology. 1984;87:914–21.

73. Schloitte AC, Sutherland K, Woods CM, Blackshaw LA, Davison JS, Toulou J, et al. A novel preparation to study rat pancreatic spinal and vagal mechano-sensitive afferents in vitro. Neurogastroenterol Motil. 2008;20:1060–9.

74. Karlsson S, Scheurink AJ, Steffens AB, Ahrén B. Involvement of capsaicin-sensitive nerves in the rat in combination of immunohistochemistry and retrograde tracing. Gastroenterology. 2008;133:375–88.

75. Karlsson S, Sundler F, Ahrén B. Neonatal capsaicin-treatment in mice: effects on pancreatic peptidergic nerves and 2-deoxy-D-glucose-induced insulin and glucagon secretion. J Auton Nerv Syst. 1992;39:51–9.

76. Kirkwood KS, Kim EH, He XD, Calaustro EQ, Domush C, Yoshimi SK, et al. Substance P inhibits pancreatic exocrine secretion via a neural mechanism. Am J Physiol. 1999;277:G314–G320.

77. Hong SM, Noe M, Hruban CA, Thompson ED, Wood LD, Hruban RH. A “Clearer” view of pancreatic pathology: a review of tissue clearing and advanced microscopy techniques. Adv Anat Pathol. 2019;26:31–9.

78. Tang SC, Shen NC, Lin PY, Peng S-J, Chien H-J, Chou Y-H, et al. Pancreatic neuro-insular network in young mice revealed by 3D panoramic histology. Diabetologia. 2018;61:158–67.

79. Tang SC, Baeyens L, Shen CN, Peng S-J, Chien H-J, Scheel DW, et al. Human pancreatic neuro-insular network in health and fatty infiltration. Diabetologia. 2018;61:168–81.
of pancreatic cancer cells through TGFβ signaling. Cell Death Dis. 2019;10:886.

103. Deborde S, Ormelchenko T, Lyubchik A, Zhou Y, He S, McNamara WF, et al. Schwann cells induce cancer cell dispersion and invasion. J Clin Invest. 2016;126:1538–54.

104. Ayala GE, Dai H, Powell M, Li R, Ding Y, Wheeler TM, et al. Cancer-related axonogenesis and neurogenesis in prostate cancer. Clin Cancer Res. 2008;14:7593–603.

105. Albo D, Akay CL, Marshall CL, Wilks JA, Verstovsek G, Liu H, et al. Neurogenesis in colorectal cancer is a marker of aggressive tumor behavior and poor outcomes. Cancer. 2011;117:4834–45.

106. Huang D, Su S, Cui X, Shen X, Zeng Y, Wu W, et al. Nerve fibers in breast cancer tissues indicate aggressive tumor progression. Medicine (Baltimore). 2014;93:e172.

107. Partecke LI, Speerforck S, Käding A, Trung DN, Diedrich S, Sendler M, Weiss F, et al. Schwann cells induce cancer cell dispersion and invasion. J Natl Cancer Inst. 2008;100:1895–901.

108. Paridaen JL, Albers KM, Li D, Hartman DJ, Crawford HC, Muha EA, et al. PanN neuroendocrine cells promote tumorigenesis via neuronal cross-talk. Cancer Res. 2017;77:1868–79.

109. Stopczynski RE, Normolle DP, Hartman DJ, Ying H, DeBerry JJ, Bielefeldt K, et al. Neuroplastic changes occur early in the development of pancreatic ductal adenocarcinoma. Cancer Res. 2014;74:1718–27.

110. Ceyhan GO, Bergmann F, Kadihasanoglu M, Altintas B, Demir IE, Hinz U, et al. Pancreatic neuropathy and neuropathic pain—a comprehensive pathomorphological study of 546 cases. Gastroenterology. 2009;136(1):177–186.e1.

111. Ceyhan GO, Demir IE, Rauch U, Bergmann F, Müller MW, Büchler MW, et al. Pancreatic neuropathy results in “neural remodeling” and altered pancreatic innervation in chronic pancreatitis and pancreatic cancer. Am J Gastroenterol. 2009;104:2555–65.

112. Secq V, Leca J, Bressy C, Guillaumond F, Skrobuk P, Nigri J, et al. Stromal SLIT2 impacts on pancreatic cancer-associated neural remodeling. Cell Death Dis. 2015;6:e1592.

113. Griffin N, Faulkner S, Jobling P, Hondermarck H. Targeting neurotrophin signaling in cancer: The renaissance. Pharmacol Res. 2018;135:12–7.

114. Renz BW, Takahashi R, Tanaka T, Macchini M, Hayakawa Y, Dantes D, et al. j2 adrenergic-neurotrophin feedback loop promotes pancreatic cancer. Cancer Cell. 2018;34:863–7.

115. Mikyoczki SJ, Lang D, Huang L, Klein-Sacto AJ, Dionne CA, Ruggeri BA. Neurotrophins and Trk receptors in human pancreatic ductal adenocarcinoma: expression patterns and effects on in vitro invasive behavior. Int J Cancer. 1999;81:417–27.

116. Saloman JL, Albers KM, Li D, Hartman DJ, Crawford HC, Muha EA, et al. Ablation of sensory neurons in a genetic model of pancreatic ductal adenocarcinoma slows initiation and progression of cancer. Proc Natl Acad Sci U S A. 2016;113:3078–83.

117. Bai H, Li H, Zhang W, Matkowskij KA, Xiao J, Srivastava SK, et al. Inhibition of chronic pancreatitis and pancreatic intraepithelial neoplasia (PanIN) by capsaicin in LSL-KrasG12D/Pdx1-Cre mice. Carcinogenesis. 2011;32:1689–96.

118. Renz BW, Tanaka T, Sunagawa M, Takahashi R, Jiang Z, Macchini M, et al. Cholinergic signaling via muscarinic receptors directly and indirectly suppresses pancreatic tumorigenesis and cancer stemness. Cancer Discov. 2018;8:1458–73.

119. Partecke LI, Käding A, Trung DN, Diedrich S, Sendler M, Weiss F, et al. Subdiaphragmatic vagotomy promotes tumor growth and reduces survival via TNFα in a murine pancreatic cancer model. Oncotarget. 2017;8:22501–12.

120. Foley K, Rucki AA, Xiao Q, Zhou D, Leubner A, Mo G, et al. Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer. Sci Signal. 2015;8(388):ra77.

121. Göhrig A, Detjén KM, Hilfenhaus G, Körner JL, Weitzel M, Arsenic R, et al. Axon guidance factor SLIT2 inhibits neural invasion and metastasis in pancreatic cancer. Cancer Res. 2014;74:1529–40.

122. Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15:731–47.

123. Amato A, Sartore-Bianchi A, Bencardino K, Pizzutilo EG, Tosi F, Siena S. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer. Ann Oncol. 2019;8:vii5–viii15.

124. Drilon A. TRK inhibitors in TRK fusion-positive cancers. Ann Oncol. 2019;30:viii23–viii30.

125. Kheder ES, Hong DS. Emerging targeted therapy for tumors with NTRK fusion proteins. Clin Cancer Res. 2018;24:5807–14.

126. Kramer A, Green J, Pollard J Jr, Tugendreich S. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics (Oxford, England). 2014;30:523–30.

127. O’Reilly EM, Hechtman JF. Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion. Ann Oncol. 2019;8:viii36–viii40.

128. Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21:271–82.

129. Solomon JP, Linkov I, Rosado A, Mullaney K, Rosen EY, Frosina D, et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol. 2020;33:38–46.

130. Singh AD, George B, Greenbowe JR, Chung J, Suh J, Maitra A, et al. Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers. Gastroenterology. 2019;156(8):2242–2253.e4.

131. Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23:703–13.

132. Momi N, Ponnusamy MP, Kaur S, Rachagani S, Kunigal SS, Chellappan S, et al. Nicotine/cigarette smoke promotes metastasis of pancreatic cancer through α7nAChR-mediated MUC4 upregulation. Oncogene. 2013;32:1384–95.

133. Stock AM, Powe DG, Hahn SA, Troost G, Niggemann B, Zänker KS, et al. Norepinephrine inhibits the migratory activity of pancreatic cancer cells. Exp Cell Res. 2013;319:1744–58.

134. Guo K, Ma Q, Li J, Wang Z, Shan T, Li W, et al. Interaction of the sympathetic nerve with pancreatic cancer cells promotes perineural invasion through the activation of STAT3 signaling. Mol Cancer Ther. 2013;12:264–73.

135. Li X, Ma G, Ma Q, Li W, Liu J, Han L, et al. Neurotransmitter substance P mediates pancreatic cancer perineural invasion via NK-1R in cancer cells. Mol Cancer Res. 2013;11:294–302.

136. Cavel O, Shomron O, Shabaty A, Vital J, Trejo-Leider L, Weizman N, et al. Endoneural macrophages induce perineural invasion of pancreatic cancer cells by secretion of GDNF and activation of RET tyrosine kinase receptor. Cancer Res. 2012;72:5733–43.

137. Wang K, Demir IE, D’Haese JG, Tieftrunk E, Kujundzic K, Schorn S, et al. The neurotrophic factor neurotrophin contributes toward an aggressive cancer cell phenotype, neuropathic pain and neuronal plasticity in pancreatic cancer. Carcinogenesis. 2014;35:103–13.

138. Ceyhan GO, Giese NA, Erkan M, Kerscher AG, Wente MN, Giese T, et al. The neurotrophic factor artemin promotes pancreatic cancer invasion. Ann Surg. 2006;244:274–81.

139. Kheder ES, Hong DS. Emerging targeted therapy for tumors with NTRK fusion proteins. Clin Cancer Res. 2018;24:5807–14.

140. Kramer A, Green J, Pollard J Jr, Tugendreich S. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics (Oxford, England). 2014;30:523–30.
141. De Oliveira T, Abiatari I, Raulefs S, Sauliunaite D, Erkan M, Kong B, et al. Syndecan-2 promotes perineural invasion and cooperates with K-ras to induce an invasive pancreatic cancer cell phenotype. Mol Cancer. 2012;11:19.

142. Li X, Wang Z, Ma Q, Xu Q, Liu H, Duan W, et al. Sonic hedgehog paracrine signaling activates stromal cells to promote perineural invasion in pancreatic cancer. Clin Cancer Res. 2014;20:4326–38.

143. Müller MW, Giese NA, Swiercz JM, Ceyhan GO, Esposito I, Hinz U, et al. Association of axon guidance factor semaphorin 3A with poor outcome in pancreatic cancer. Int J Cancer. 2007;121:2421–33.

How to cite this article: Wakiya T, Ishido K, Yoshizawa T, Kanda T, Hakamada K. Roles of the nervous system in pancreatic cancer. Ann Gastroenterol Surg. 2021:00:1–11. https://doi.org/10.1002/ags3.12459